Breast Cancer Research and Treatment

Article	Citations
Genetic counseling referral rates and genetic testing outcomes in women with young breast cancer: a 20-year Canadian review	117
Letter to the BRCT editor	86
Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation	62
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience	62
Management and outcomes of men diagnosed with primary breast cancer	57
Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers	55
Women with metastatic breast cancer don't just follow step-count trends, they exceed them: an exploratory study	54
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer	51
Racial/ethnic and socioeconomic differences in breast cancer surgery performed and delayed treatment: mediating impact on mortality	50
Trends in surgery and adjuvant treatment for early-stage breast cancer: a population-based study in Queensland, Australia	49
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer	47
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients	43
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe	42
Retraction Note to: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression	42
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	37
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival	36
Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS	36
Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors	34
Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis	33
Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial	33
Radiotherapy, chemotherapy, and heart disease	31
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?	31
Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer	31
Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews	31
Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis	30

Early experience of robotic axillary lymph node dissection in patients with node-positive breast cancer	30
Effect of neighborhood deprivation index on breast cancer survival in the United States	29
Mitochondrial tRNA fragment, mt-tRF-Tyr-GTA-001 (tRF-21-X3OJI8EWB), in breast cancer and its potential clinical implications	29
Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer	28
Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy	28
Overexpression of POU3F2 promotes radioresistance in triple-negative breast cancer via Akt pathway activation	27
Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis	26
Barriers and engagement in breast cancer survivorship wellness activities	26
Retraction Note: Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin	25
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study	25
Comparison of upper extremity lymphedema after sentinel lymph node biopsy and axillary lymph node dissection: patient-reported outcomes in 3044 patients	25
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database	25
Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer	23
Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy	23
Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history	23
The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer	23
The relationship between sleep and weight change among women diagnosed with breast cancer participating in the Women’s Health Initiative	22
Does structural racism impact receipt of NCCN guideline-concordant breast cancer treatment?	22
Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up	22
Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools	22
Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast canc	21
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in rea	21
Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer surgery	20
Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis”	20
Phenotypes of carriers of two mutated alleles in major cancer susceptibility genes	20
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde	19
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging	19
Prognostic and predictive impact of NOTCH1 in early breast cancer	19
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience	19
Low incidence of distant metastases in older women with non-metastatic breast cancer treated with primary endocrine therapy	19
Facilitators and barriers to medication adherence with adjuvant endocrine therapy in women with breast cancer: a structural equation modelling approach	19
Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer	19
The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system	18
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventi	18
Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions	18
Letter to the editor regarding: ‘Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis’	18
Response to letter “re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: A nationwide population–based retrospective cohort study in Belgium and the National Cancer Data	18
Subspecialized breast pathologists have suboptimal interobserver agreement in Ki-67 evaluation using 20% as the cutoff	18
Clinical relevance of double heterozygosity revealed by next-generation sequencing of homologous recombination repair pathway genes in South African breast cancer patients	18
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer	18
Clinical characteristics and prognosis of postpartum breast cancer	18
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials	17
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study	17
Factors associated with late risks of breast cancer-specific mortality in the SEER registry	17
Use of endocrine therapy for estrogen receptor-positive breast cancer among American Indians and Alaska natives	17
Development of a key performance indicator for breast cancer in Queensland, Australia	17
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population	17
Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study	17
Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?	17
Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer	17

Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients	16
Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go???	16
Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study	16
Predictive and prognostic effect of HO-1 expression in breast cancer patients undergoing neoadjuvant chemotherapy	16
Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care	16
Endocrine adherence in male versus female breast cancer: a seer-medicare review	16
A web-based personalized decision support tool for patients diagnosed with ductal carcinoma in situ: development, content evaluation, and usability testing	16
A retrospective study in tumour characteristics and clinical outcomes of overweight and obese women with breast cancer	16
Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer	15
Leptomeningeal Metastasis in ER + HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period	15
Risk-reducing surgeries for breast cancer in Brazilian patients undergoing multigene germline panel: impact of results on decision making	15
Comparison of partial-breast irradiation and intraoperative radiation to whole-breast irradiation in early-stage breast cancer patients: a Kaplan-Meier-derived patient data meta-analysis	15
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis	15
Analysing potent biomarkers along phytochemicals for breast cancer therapy: an in silico approach	15
Comments on the effects of exercise and diet on oxidative stress and telomere length in breast cancer survivors	15
SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast	15
Quantitative analysis of pressure levels in manual lymphatic drainage across stages of breast cancer-related lymphedema: implications for optimized treatment protocols	15
The effects of exercise and diet on oxidative stress and telomere length in breast cancer survivors	15
Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study	14
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients	14
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study	14
Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting	14
The largest genome-wide association study for breast cancer in Taiwanese Han population	14
Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer	14
Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis	14
Characteristics and risk factors of axillary lymph node metastasis of microinvasive breast cancer	14
The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study	14
Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase	14
Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience	14
A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer	14
Psychosocial stressors and breast cancer gene expression in the Black Women’s Health Study	13
The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa	13
Intraoperative assessment of axillary sentinel lymph nodes by telepathology	13
Should low-risk DCIS lose the cancer label? An evidence review	13
Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer	13
Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients	13
Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants	13
Lazzaro responds to Pouwels et al.	13
Presence of crown-like structures in breast adipose tissue; differences between healthy controls, BRCA1/2 gene mutation carriers and breast cancer patients	13
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review	13
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy	13
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)	13
Sleep medication use and risk of fractures in breast cancer survivors	13
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis	13
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer	13
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlle	13
HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines	13
Impact of body mass index on survival in women receiving chemotherapy for early breast cancer	13
Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer	13
Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study	13
Is there an association between endometriosis and subsequent breast cancer? A retrospective cohort study from Germany	13
Genetic testing in women with early-onset breast cancer: a Traceback pilot study	13
Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients	13
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies	12
Does the toxicity of endocrine therapy persist into long-term survivorship?: Patient-reported outcome results from a follow-up study beyond a 10-year-survival	12
Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA	12
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer	12
Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics	12
Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis	12
Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO	12
Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer	12
Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer	12
Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database	12
Impact of age, race, and family history on COVID-19–related changes in breast cancer screening among the Boston mammography cohort study	12
The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)	12
Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system	12
Metastatic pure invasive lobular breast cancer or metastatic mixed invasive ductal and lobular breast cancer: are they different entities?	12
Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression	12
Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer	12
Breast cancer treatment patterns by age and time since last pregnancy in the Carolina Breast Cancer Study Phase III	12
Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells	12
Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study	12
Comment on: sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer—results from the ABLE feasibility trial	12
Integrated analysis of diverse cancer types reveals a breast cancer-specific serum miRNA biomarker through relative expression orderings analysis	12
Hypofractionated proton therapy in breast cancer: where are we? A critical review of the literature	12
Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer	12
Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers	11
Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evalua	11
Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients—a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy	11
Pro-vegetarian dietary pattern and risk of breast cancer: a case–control study	11

Polycystic ovary syndrome and risk of breast cancer in premenopausal and postmenopausal women: a nationwide population-based cohort study	11
Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression	11
Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer	11
Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer	11
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy	11
Survival outcomes for breast conserving surgery versus mastectomy among elderly women with breast cancer	11
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer	11
Cardiotoxicity among socioeconomically marginalized breast cancer patients	11
Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up	11
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial	11
Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death	11
The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary	11
BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance	11
Use of imaging prediction model for omission of axillary surgery in early-stage breast cancer patients	11
The association between meat and fish intake by preparation methods and breast cancer in the Carolina Breast Cancer Study (CBCS)	11
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform	11
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature	11
Serum hormone levels and normal breast histology among premenopausal women	11
Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer	11
Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation	11
Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression	11
Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience	11
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer	11
Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer	11
Multimodal MRI examination of structural and functional brain changes in older women with breast cancer in the first year of antiestrogen hormonal therapy	11
STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression	11
Investigating the role of core needle biopsy in evaluating tumor-stroma ratio (TSR) of invasive breast cancer: a retrospective study	11
Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer	10
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer	10
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry	10
Surveillance mammography after treatment for male breast cancer	10
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia	10
Awareness of link between obesity and breast cancer risk is associated with willingness to participate in weight loss intervention	10
Correction: Ferroptosis as a promising targeted therapy for triple negative breast cancer	10
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study	10
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy	10
The dynamics of HER2-low expression during breast cancer progression	10
Evaluation of SNPs associated with mammographic density in European women with mammographic density in Asian women from South-East Asia	10
Clever-1 positive macrophages in breast cancer	10
HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity	10
COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation	10
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers	10
Correction to: Ethnic inequities in use of breast conserving surgery and radiation therapy in Aotearoa/New Zealand: which factors contribute?	10
Immunotherapy toxicity: identification and management	10
Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated	10
Breast reconstruction and quality of life five years after cancer diagnosis: VICAN French National cohort	10
Routine and interval detection of locoregional breast cancer recurrences and risk of subsequent distant metastasis	10
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA3	10
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study	10
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation	10
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis	10
Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation	10
Surgical and obstetric outcomes of breast cancer surgery during pregnancy: a nationwide database study in Japan	10
Letter to the editor: “Frequency of zoledronate administration in early breast cancer”	10
ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells	10
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer	9
Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors	9
Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000–2016	9
Textbook outcomes in DIEP flap breast reconstruction: a Delphi study to establish consensus	9
Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene	9
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018	9
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer	9
De-escalation of breast cancer treatment for Her2-positive breast cancer	9
Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system	9
Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study)	9
Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer	9
Application of genetic testing criteria for hereditary breast cancer in South Africa	9
Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer	9
De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study	9
Diagnostic value of alkaline phosphatase and bone-specific alkaline phosphatase for metastases in breast cancer: a systematic review and meta-analysis	9
The WISDOM study: a new approach to screening can and should be tested	9
Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor	9
Breast reconstruction is a viable option for older patients	9
EGFR as a potent CAR T target in triple negative breast cancer brain metastases	9
IGF1R activates FOXP3-β-catenin signaling to promote breast cancer development	9
The impact of nurse navigation on timeliness to treatment for benign high-risk breast pathology	9
Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer	9
The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development	9
MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975	9
Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer	9
Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic	9
DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS	9
Advances in the prevention and treatment of breast cancer-related lymphedema	9
L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study	9
Demographic and clinical trends of young breast cancer patients from the national cancer database: disproportionate effect on minority populations	9
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer	9
Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine	9
High-risk lesions in the breast diagnosed by MRI-guided core biopsy: upgrade rates and features associated with malignancy	9
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial	9
Barrier films or dressings for the prevention of acute radiation dermatitis in breast cancer: a systematic review and network meta-analysis	9
Ferroptosis as a promising targeted therapy for triple negative breast cancer	9
Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study	9
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study	9
Correction: Preferences of patients with high-risk HR+/HER2− breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany	9
SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast	9